Periscope Capital Inc. acquired a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII – Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 150,000 shares of the company’s stock, valued at approximately $1,527,000.
Several other institutional investors have also recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Drugs Made In America Acquisition II during the first quarter worth about $19,960,000. First Trust Capital Management L.P. purchased a new stake in Drugs Made In America Acquisition II in the 3rd quarter valued at about $13,218,000. Wealthspring Capital LLC purchased a new stake in Drugs Made In America Acquisition II in the 3rd quarter valued at about $4,063,000. Kryger Capital LLC purchased a new stake in Drugs Made In America Acquisition II in the 1st quarter valued at about $3,088,000. Finally, Rivernorth Capital Management LLC bought a new position in shares of Drugs Made In America Acquisition II during the 1st quarter worth approximately $2,991,000.
Drugs Made In America Acquisition II Trading Up 0.0%
NASDAQ DMII opened at $10.24 on Monday. The business’s fifty day moving average is $10.19 and its 200-day moving average is $10.08. Drugs Made In America Acquisition II Corp. has a one year low of $9.86 and a one year high of $10.33.
Drugs Made In America Acquisition II (NASDAQ:DMII – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported $0.07 earnings per share for the quarter.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded Drugs Made In America Acquisition II to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings raised Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Drugs Made In America Acquisition II has an average rating of “Sell”.
View Our Latest Stock Analysis on DMII
Drugs Made In America Acquisition II Company Profile
Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company. The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.
Further Reading
- Five stocks we like better than Drugs Made In America Acquisition II
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
